Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G/A for Xeris Biopharma Holdings Inc Common Stock (XERS).
- Disclosed ownership: 6.7%.
- Date of event: 31 Dec 2025.
VANGUARD GROUP INC - 31 Dec 2025 SCHEDULE 13G/A Report for Xeris Biopharma Holdings Inc Common Stock (XERS)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Symbol
- XERS
- Shares outstanding
- 165,974,436 shares
- Disclosed Ownership
- 11,186,677 shares
- Ownership
- 6.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 30 Jan 2026, 14:43:35 UTC
- Date of event
- 31 Dec 2025
- Next filing
- 27 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 6.7% ownership in Xeris Biopharma Holdings Inc Common Stock (XERS) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 30 Jan 2026, 14:43.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 6.7% | 11,186,677 | 0 | 1,339,227 | Ashley Grim | Head of Global Fund Administration |